About SpiroxMed
SpiroxMed is a company based in Menlo Park (United States) founded in 2013 was acquired by Entellus Medical in July 2017.. SpiroxMed has raised $69.69 million across 3 funding rounds from investors including KKR, Entellus Medical and Western Technology Investment. SpiroxMed operates in a competitive market with competitors including Navage, Chordate, Arrinex, Nasal Medical and ENTpro, among others.
- Headquarter Menlo Park, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Spirox, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$69.69 M (USD)
in 3 rounds
-
Latest Funding Round
$45 M (USD), Series C
Mar 15, 2016
-
Investors
KKR
& 7 more
-
Employee Count
Employee Count
-
Acquired by
Entellus Medical
(Jul 07, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Software Development Team
279 people
Sales and Marketing
127 people
Leadership Team
90 people
Human Resources and Administration
68 people
Finance and Accounting
50 people
Senior Team
49 people
Legal and Compliance
33 people
Data Analysis and Operations Team
30 people
Unlock access to complete
Funding Insights of SpiroxMed
SpiroxMed has successfully raised a total of $69.69M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $45 million completed in March 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $45.0M
-
First Round
First Round
(04 Oct 2013)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2016 | Amount | Series C - SpiroxMed | Valuation | KKR | |
| Jun, 2015 | Amount | Series B - SpiroxMed | Valuation | Venrock , Aisling Capital | |
| Oct, 2013 | Amount | Series A - SpiroxMed | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in SpiroxMed
SpiroxMed has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include KKR, Entellus Medical and Western Technology Investment. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by this private equity firm.
|
Founded Year | Domain | Location | |
|
Investments are focused on tech and life sciences startups.
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by SpiroxMed
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - SpiroxMed
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Spiroxmed Comparisons
Competitors of SpiroxMed
SpiroxMed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Navage, Chordate, Arrinex, Nasal Medical and ENTpro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Nasal irrigator that uses suction
|
|
| domain | founded_year | HQ Location |
Develops and markets CE-marked devices for migraine and rhinitis treatment.
|
|
| domain | founded_year | HQ Location |
Hand-held disposable cryotherapy devices for ENT procedures are developed.
|
|
| domain | founded_year | HQ Location |
Products for comfortable breathing and sleep aids are developed.
|
|
| domain | founded_year | HQ Location |
Simple medical devices for nasal cleaning and reduction of snoring
|
|
| domain | founded_year | HQ Location |
Manufactures nasal irrigation systems for sinus and allergy relief worldwide.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Spiroxmed
Frequently Asked Questions about SpiroxMed
When was SpiroxMed founded?
SpiroxMed was founded in 2013.
Where is SpiroxMed located?
SpiroxMed is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Is SpiroxMed a funded company?
SpiroxMed is a funded company, having raised a total of $69.69M across 3 funding rounds to date. The company's 1st funding round was a Series A of $6.19M, raised on Oct 04, 2013.
What does SpiroxMed do?
Provider of non-invasive treatment of nasal valve obstruction. The morbidity associated with conventional surgical options has resulted in limited use. Its LATERA Absorbable Nasal Implant is used to support upper and lower lateral cartilage in the nose. The minimally invasive technology is intuitive to learn and use, and is delivered inside the nasal wall by ENTs or plastic surgeons. Supporting the cartilage in this manner may reduce nasal airway obstruction symptoms and help patients breathe better. The LATERA implant is made of a material that absorbs over a period of approximately 18 months, so can deliver support without limiting future treatment options. Spirox was formerly known as Nasoform.
Who are the top competitors of SpiroxMed?
Who are SpiroxMed's investors?
SpiroxMed has 8 investors. Key investors include KKR, Entellus Medical, Western Technology Investment, Health Quest Capital, and Aisling Capital.